76 related articles for article (PubMed ID: 17483304)
1. Biallelic mutation of MSH2 in primary human cells is associated with sensitivity to irradiation and altered RAD51 foci kinetics.
Barwell J; Pangon L; Hodgson S; Georgiou A; Kesterton I; Slade T; Taylor M; Payne SJ; Brinkman H; Smythe J; Sebire NJ; Solomon E; Docherty Z; Camplejohn R; Homfray T; Morris JR
J Med Genet; 2007 Aug; 44(8):516-20. PubMed ID: 17483304
[TBL] [Abstract][Full Text] [Related]
2. The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase.
Franchitto A; Pichierri P; Piergentili R; Crescenzi M; Bignami M; Palitti F
Oncogene; 2003 Apr; 22(14):2110-20. PubMed ID: 12687013
[TBL] [Abstract][Full Text] [Related]
3. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
4. [Mismatch repair (MMR) efficiency and MSH2 gene mutation in human colorectal carcinoma cell line COLO320HSR].
Tronov VA; Kramarenko II; Maĭorova EN; Zakharov SF
Genetika; 2007 Apr; 43(4):537-44. PubMed ID: 17555131
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of homologous recombination by treatment with BVDU (brivudin) or by RAD51 silencing increases chromosomal damage induced by bleomycin in mismatch repair-deficient tumour cells.
Vernole P; Muzi A; Volpi A; Dorio AS; Terrinoni A; Shah GM; Graziani G
Mutat Res; 2009 May; 664(1-2):39-47. PubMed ID: 19428379
[TBL] [Abstract][Full Text] [Related]
6. Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia.
Worrillow LJ; Allan JM
Oncogene; 2006 Mar; 25(12):1709-20. PubMed ID: 16278672
[TBL] [Abstract][Full Text] [Related]
7. Functional analysis of HNPCC-related missense mutations in MSH2.
Lützen A; de Wind N; Georgijevic D; Nielsen FC; Rasmussen LJ
Mutat Res; 2008 Oct; 645(1-2):44-55. PubMed ID: 18822302
[TBL] [Abstract][Full Text] [Related]
8. Compromised repair of clustered DNA damage in the human acute lymphoblastic leukemia MSH2-deficient NALM-6 cells.
Holt SM; Scemama JL; Panayiotidis MI; Georgakilas AG
Mutat Res; 2009 Mar; 674(1-2):123-30. PubMed ID: 18955159
[TBL] [Abstract][Full Text] [Related]
9. Homozygous germ line mutation in exon 27 of murine Brca2 disrupts the Fancd2-Brca2 pathway in the homologous recombination-mediated DNA interstrand cross-links' repair but does not affect meiosis.
Atanassov BS; Barrett JC; Davis BJ
Genes Chromosomes Cancer; 2005 Dec; 44(4):429-37. PubMed ID: 16127665
[TBL] [Abstract][Full Text] [Related]
10. Msh2 deficiency leads to chromosomal abnormalities, centrosome amplification, and telomere capping defect.
Campbell MR; Wang Y; Andrew SE; Liu Y
Oncogene; 2006 Apr; 25(17):2531-6. PubMed ID: 16331258
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer in an MSH2 gene mutation carrier.
Westenend PJ; Schütte R; Hoogmans MM; Wagner A; Dinjens WN
Hum Pathol; 2005 Dec; 36(12):1322-6. PubMed ID: 16311127
[TBL] [Abstract][Full Text] [Related]
12. Role of MUTYH and MSH2 in the control of oxidative DNA damage, genetic instability, and tumorigenesis.
Russo MT; De Luca G; Casorelli I; Degan P; Molatore S; Barone F; Mazzei F; Pannellini T; Musiani P; Bignami M
Cancer Res; 2009 May; 69(10):4372-9. PubMed ID: 19435918
[TBL] [Abstract][Full Text] [Related]
13. Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner.
Sansom OJ; Toft NJ; Winton DJ; Clarke AR
Oncogene; 2001 Jun; 20(27):3580-4. PubMed ID: 11429706
[TBL] [Abstract][Full Text] [Related]
14. Hypersensitivity to camptothecin in MSH2 deficient cells is correlated with a role for MSH2 protein in recombinational repair.
Pichierri P; Franchitto A; Piergentili R; Colussi C; Palitti F
Carcinogenesis; 2001 Nov; 22(11):1781-7. PubMed ID: 11698339
[TBL] [Abstract][Full Text] [Related]
15. Familial T-cell non-Hodgkin lymphoma caused by biallelic MSH2 mutations.
Scott RH; Homfray T; Huxter NL; Mitton SG; Nash R; Potter MN; Lancaster D; Rahman N
J Med Genet; 2007 Jul; 44(7):e83. PubMed ID: 17601929
[TBL] [Abstract][Full Text] [Related]
16. Non-tumor cells from an MSH2-null individual show altered cell cycle effects post-UVB.
Narine KA; Felton KE; Parker AA; Tron VA; Andrew SE
Oncol Rep; 2007 Dec; 18(6):1403-11. PubMed ID: 17982623
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous and mutagen-induced loss of DNA mismatch repair in Msh2-heterozygous mammalian cells.
Borgdorff V; van Hees-Stuivenberg S; Meijers CM; de Wind N
Mutat Res; 2005 Jul; 574(1-2):50-7. PubMed ID: 15914206
[TBL] [Abstract][Full Text] [Related]
18. DNA mismatch repair deficiency stimulates N-ethyl-N-nitrosourea-induced mutagenesis and lymphomagenesis.
Claij N; van der Wal A; Dekker M; Jansen L; te Riele H
Cancer Res; 2003 May; 63(9):2062-6. PubMed ID: 12727820
[TBL] [Abstract][Full Text] [Related]
19. Conditional expression of mutated K-ras accelerates intestinal tumorigenesis in Msh2-deficient mice.
Luo F; Brooks DG; Ye H; Hamoudi R; Poulogiannis G; Patek CE; Winton DJ; Arends MJ
Oncogene; 2007 Jun; 26(30):4415-27. PubMed ID: 17297472
[TBL] [Abstract][Full Text] [Related]
20. The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase.
Yang Q; Zhang R; Wang XW; Linke SP; Sengupta S; Hickson ID; Pedrazzi G; Perrera C; Stagljar I; Littman SJ; Modrich P; Harris CC
Oncogene; 2004 May; 23(21):3749-56. PubMed ID: 15064730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
